<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04118829</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-19-347</org_study_id>
    <nct_id>NCT04118829</nct_id>
  </id_info>
  <brief_title>Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER</brief_title>
  <official_title>Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carilion Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carilion Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perampanel is a drug used to treat patients with epilepsy/seizures. This study is designed to&#xD;
      determine how much perampanel actually crosses the blood brain barrier into the cerebral&#xD;
      spinal fluid when the drug is taken.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Perampanel is a drug used to treat patients with epilepsy/seizures. This study is designed to&#xD;
      determine how much perampanel actually crosses the blood brain barrier into the cerebral&#xD;
      spinal fluid when the drug is taken.&#xD;
&#xD;
      During a routinely scheduled neurosurgical procedure, one to two mL of cerebral spinal fluid&#xD;
      will be obtained from the subarachnoid space of the brain. Five mL of arterial blood will&#xD;
      also be drawn from the patients arterial line during their procedure. The blood samples and&#xD;
      cerebral spinal fluid samples will be compared to see how much perampanel is in the blood&#xD;
      versus the cerebrospinal fluid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood brain barrier serum levels</measure>
    <time_frame>3 weeks</time_frame>
    <description>To determine the blood brain barrier(BBB) penetration of PER by measuring ratio of serum level to that of CSF measured on simultaneously obtained samples</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Epilepsy</condition>
  <condition>Seizures</condition>
  <arm_group>
    <arm_group_label>Group one</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Group 1 patients will be taking PER up to 14 days following surgical intervention as per discretion of the treating neurosurgeon.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Two</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Group 2 patients will be taking PER as part of their maintenance AED regimen and will continue on the same maintenance dosage postoperatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Perampanel</intervention_name>
    <description>For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).&#xD;
It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day.</description>
    <arm_group_label>Group Two</arm_group_label>
    <arm_group_label>Group one</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (&gt;18 years-old) who are scheduled to undergo brain surgery and need&#xD;
             antiepileptic medication for prophylaxis or treatment of seizures&#xD;
&#xD;
          -  Able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient unable to provide informed consent&#xD;
&#xD;
          -  Allergy to PER or its component&#xD;
&#xD;
          -  Patient with significant renal (creatinine clearance 35 ml/min) or hepatic impairment&#xD;
&#xD;
          -  Pregnant or lactating females will be excluded from the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aashit Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jordan Darden, PhD</last_name>
    <phone>540-981-7942</phone>
    <email>jadarden@carilionclinic.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Darden, PhD</last_name>
      <phone>540-981-7942</phone>
      <email>jadarden@carilionclinic.org</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Ndolo, RN</last_name>
      <phone>540-519-3428</phone>
      <email>rmndolo@carilionclinic.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2019</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carilion Clinic</investigator_affiliation>
    <investigator_full_name>Aashit Shah</investigator_full_name>
    <investigator_title>Chief of Neurology</investigator_title>
  </responsible_party>
  <keyword>Perampanel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not share any individual participant data. Data analysis will involve aggregated data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

